“This new research confirms that using Philips BioTel Heart MCOT as the first line of evaluation is more cost-effective and can provide the level of diagnostic confidence needed to help detect and diagnose atrial fibrillation, and potentially prevent a second stroke. Philips ambulatory monitoring and diagnostics general manager Andy Broadway said: “The diagnostic tools clinicians use to monitor this group of patients play an important role in finding the cause of the stroke and developing a personalised treatment plan. In the case of persons detected with AF, the cost per patient reduced when using the MCOT patch followed by ILR ($29,598) than persons monitored with ILR alone ($228,507), said the company. The device detected 4.6 times more patients with AF than ILR alone. In addition, the study revealed that the MCOT usage followed by ILR in half of the patients initially undiagnosed with AF saved more than $4m. The study was carried out for one year on 1,000 people suffering from stroke to differentiate between the costs and outcomes of two monitoring options. It also helped to minimise secondary stroke risk due to new anticoagulant use in subjects with the MCOT patch detected AF.Īs per the study, the use of initial MCOT monitoring achieved nearly eight times lower costs, minimising the total cost per patient with detected AF by $198,909, compared to monitoring with ILR only. What is included with ePatch Direct ePatch Direct brings together an Extended Wear Holter device and patient monitoring service that includes clinical analysis with a patient report in one convenient kit: BioTel Heart ePatch Extended Wear Holter sensor. The study revealed that a 30-day continuous monitoring programme using the Philips BioTel Heart MCOT patch followed by an implantable loop recorder (ILR) has enhanced the detection rates of atrial fibrillation (AF), an abnormal heart rhythm that can increase the risk of stroke. Because this water-resistant device can be worn all day and night long over the course of several days or weeks, the data it provides is a valuable tool in diagnosing. Royal Philips has unveiled the details of a new study evaluating its BioTel Heart mobile cardiac outpatient telemetry (MCOT) patch for first-line diagnostic ambulatory monitoring solution on post-cryptogenic stroke patients. Simple, seamless EMR integration for cardiac monitoring data Philips BioTel Heart helps reduce the cost of care through practice efficiencies and provides. Attached to the skin with a medical-grade adhesive, the wireless 2-by-5-inch Zio Patch constantly monitors the heart’s rhythm and keeps the data stored for analysis later on. Diagnosis and monitoring of cardiac arrhythmias or heart related disorders in a healthcare setting. is comprised of four divisions: BioTel Heart®, BioTel Research, BioTel Alliance, and BioTel Care. ![]() The device detected 4.6 times more patients, compared to the implantable loop recorder and reduced the total cost per patient by $198,909, compared to monitoring with ILR only in the studyĪ care provider applies and explains Philips MCOT patch. to monitor and diagnose patients and clinical research subjects in a more efficient, accurate, and cost-effective manner.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |